Cote d’Ivoire has launched Ebola vaccination of high-risk populations, including health workers and first responders in Abidjan, where an Ebola outbreak was declared on 14 August.
The vaccination against the virus has begun swiftly with the rVSV-ZEBOV Ebola vaccine which was manufactured by Merck as the vaccine doses that the World Health Organization (WHO) helped secure to fight a four-month-long outbreak in Guinea were sent quickly by Guinea to Cote d’Ivoire.
The vaccine deployment from Guinea included 2000 doses from Merck that are being used under the “ring strategy” where people who have come into contact with a confirmed Ebola patient are given the vaccine, as well as first responders and health workers. In addition, Guinea sent around 3000 vaccine doses manufactured by Johnson & Johnson which are to be used to boost the vaccination in areas not experiencing active transmission.
Guinea has also deployed five vaccination experts and provided monoclonal antibody treatments to Cote d’Ivoire, which declared an outbreak after confirming the Ebola virus in a patient who travelled to Abidjan by road from Guinea. The patient is currently receiving treatment at a hospital in Abidjan.
“The Ebola vaccine is a critical tool in the fight against the virus and so it’s a top priority to move rapidly and start protecting people at high risk of the disease,” said Dr. Matshidiso Moeti, WHO Regional Director for Africa. “The speed with which Cote d’Ivoire has ramped up vaccination is remarkable and shows that with effective sub-regional solidarity we can quickly take measures to extinguish lethal infections that can potentially flare up into large outbreaks.”
In addition to the confirmed case, one suspected case and nine contacts have been identified and are being monitored. No deaths have been reported and there is no indication yet that the current outbreak in Cote d’Ivoire is linked with the one that was in Guinea. Further analysis and genomic sequencing will help determine any connection.
To support Cote d’Ivoire’s efforts to control the outbreak, the WHO has deployed experts to join their country-based counterparts to help ramp up infection prevention and control, diagnostics, contact tracing, treatment, community mobilization and cross-border surveillance. The Organization is also assessing whether additional vaccines will be needed to curb the disease.
The outbreak in Cote d’Ivoire is the third this year after the Democratic Republic of the Congo and Guinea.
